BeStock  

Bio-Rad Laboratories BIO

US equityMarket cap rank #1437Medical Devices
$358.90 −$8.60 (-2.34%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $358.90 0.00%
Open$364.34
Prev close$367.50
Day range$353.31 – $369.44
Volume182.3K
Market cap$9.65B
P/E (TTM)9.5
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$656.40M+0.5% YoY
Operating profit$100,000.00-99.8% YoY
Net profit$458.60M+234.1% YoY
Diluted EPS$17.02+234.0% YoY
Free cash flow$65.20M-26.9% YoY
Operating cash flow$96.40M

Revenue, last 8 quarters

$667.5MDec '24$585.4MMar '25$651.6MJun '25$653.0MSep '25$693.2MDec '25$592.1MMar '26$651.0MJun '26$656.4MSep '26

Net profit, last 8 quarters

$-715.8MDec '24$64.0MMar '25$317.8MJun '25$-341.9MSep '25$720.0MDec '25$-527.1MMar '26$371.4MJun '26$458.6MSep '26

Diluted EPS by quarter

-25.57Dec '242.29Mar '2511.67Jun '25-12.70Sep '2526.65Dec '25-19.55Mar '2613.85Jun '2617.02Sep '26

Free cash flow by quarter

$81.3MDec '24$95.5MMar '25$70.8MJun '25$89.2MSep '25$119.1MDec '25$78.1MMar '26$66.7MJun '26$65.2MSep '26

Annual revenue

$2.5BFY20$2.9BFY21$2.8BFY22$2.7BFY23$2.6BFY24$2.6BFY25

Profitability & balance sheet

Gross margin51.3%
Operating margin6.2%
Net margin39.5%
Return on equity14.3%
Return on assets10.0%
Return on invested capital11.6%
Current ratio3.18
Liabilities / assets29.5%
Cash & investments$1.66B
Total debt$1.33B
Net cash (debt)$332.70M
Free cash flow / sales12.7%

Where the revenue comes from

Quarter 2026/Q3

By business line

  • Clinical Diagnostics$401.80M 61.2%
  • Life Science$254.60M 38.8%

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Revenue as Reported $656.40M $651.00M $592.10M $2.58B $693.20M
Total Operating Revenue $656.40M $651.00M $592.10M $2.58B $693.20M
Cost of Revenue $327.80M $305.20M $282.70M $1.24B $348.00M
Gross Profit $328.60M $345.80M $309.40M $1.34B $345.20M
Operating Expense $328.50M $273.20M $275.30M $1.12B $291.30M
Selling and Admin Expenses $257.10M $212.00M $212.40M $844.30M $221.00M
Research & Development $71.40M $61.20M $62.90M $275.60M $70.30M
Asset Impairment Loss $0.00 – – $1.40M $0.00
Operating Profit $100,000.00 $72.60M $34.10M $218.60M $53.90M
Net Non-Operating Interest Income (Expense) -$2.30M $10.20M $8.70M $46.50M $18.90M
Non-Operating Interest Income $10.00M $22.30M $21.00M $95.50M $31.00M
Non-Operating Interest Expense $12.30M $12.10M $12.30M $49.00M $12.10M
Other Income (Expense) $540.90M $459.30M -$732.60M $730.40M $856.40M
Gain on Sale of Security $590.20M $458.50M -$733.30M $908.00M $1.03B
Special Income (Charges) -$49.80M – – -$178.80M -$172.80M
-Less:Impairment of Capital Assets $49.80M – – $172.80M $172.80M
-Less:Write Off $0.00 – – $6.00M $0.00
Other Non-Operating Income (Expenses) $500,000.00 $800,000.00 $700,000.00 $1.20M -$1.00M
Pretax Profit $538.70M $542.10M -$689.80M $995.50M $929.20M
Tax $80.10M $170.70M -$162.70M $235.60M $209.20M
Net Profit $458.60M $371.40M -$527.10M $759.90M $720.00M
Profit from Continuing Operations $458.60M $371.40M -$527.10M $759.90M $720.00M
Net Income to Parent Company $458.60M $371.40M -$527.10M $759.90M $720.00M
Net Income to Common Stockholders $458.60M $371.40M -$527.10M $759.90M $720.00M
Basic EPS $17.13 $13.89 -$19.55 $27.87 $26.69
Diluted EPS $17.02 $13.85 -$19.55 $27.85 $26.65

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Assets $10.78B $10.25B $9.79B $10.58B $10.58B
Total Current Assets $3.08B $3.02B $2.94B $2.91B $2.91B
Cash and Cash Equivalents & Short-Term Investments $1.66B $1.62B $1.56B $1.54B $1.54B
-Cash and Cash Equivalents $465.30M $517.00M $507.20M $529.80M $529.80M
-Short Term Investments $1.20B $1.10B $1.06B $1.01B $1.01B
Receivables $422.60M $441.80M $426.20M $460.60M $460.60M
-Accounts Receivable $422.60M $441.80M $426.20M $460.60M $460.60M
Prepaid Assets $160.70M $147.80M $150.00M $136.50M $136.50M
Inventory $783.90M $780.60M $770.50M $740.70M $740.70M
Other Current Assets $47.10M $31.80M $30.70M $27.70M $27.70M
Total Non-Current Assets $7.70B $7.23B $6.85B $7.67B $7.67B
Net PPE $652.80M $671.90M $689.40M $709.90M $709.90M
-Gross PPE $652.80M $671.90M $689.40M $1.97B $1.97B
Investments and Advances $6.27B $5.72B $5.31B $6.10B $6.10B
Goodwill and Other Intangible Assets $677.40M $734.30M $743.90M $754.10M $754.10M
-Goodwill $573.00M $574.30M $577.10M $579.80M $579.80M
-Other Intangible Assets $104.40M $160.00M $166.80M $174.30M $174.30M
Other Non-Current Assets $101.10M $101.70M $102.80M $102.70M $102.70M
Total Liabilities $3.18B $3.08B $2.94B $3.12B $3.12B
Total Current Liabilities $969.10M $961.30M $917.00M $517.00M $517.00M
Payables $171.30M $217.70M $178.00M $165.60M $165.60M
-Accounts Payable $133.50M $143.50M $133.10M $129.00M $129.00M
-Total Tax Payable $37.80M $74.20M $44.90M $36.60M $36.60M
Current Accrued Expenses $210.30M $150.50M $148.40M $172.30M $172.30M
Short-Term Debt and Capital Lease Obligation $432.70M $434.30M $436.70M $37.40M $37.40M
-Current Debt $400.90M $400.70M $400.50M $1.30M $1.30M
-Current Capital Lease Obligation $31.80M $33.60M $36.20M $36.10M $36.10M
Other Current Liabilities $154.80M $158.80M $153.90M $141.70M $141.70M
Total Non-Current Liabilities $2.21B $2.12B $2.02B $2.61B $2.61B
Long Term Debt and Capital Lease Obligation $930.70M $936.10M $941.50M $1.35B $1.35B
-Long Term Debt $803.10M $803.00M $802.90M $1.20B $1.20B
-Long Term Capital Lease Obligation $127.60M $133.10M $138.60M $145.70M $145.70M
Non-Current Deferred Liabilities $1.09B $982.20M $881.80M $1.06B $1.06B
Other Non-Current Liabilities $190.90M $198.50M $198.40M $197.80M $197.80M
Total Equity $7.60B $7.17B $6.85B $7.45B $7.45B
Stockholders' Equity $7.60B $7.17B $6.85B $7.45B $7.45B
Capital Stock $0.00 $0.00 $0.00 $0.00 $0.00
-Common Stock $0.00 $0.00 $0.00 $0.00 $0.00
-Preferred Stock $0.00 $0.00 $0.00 $0.00 $0.00
Additional Paid-In Capital $470.10M $502.90M $490.50M $476.00M $476.00M
Retained Earnings $8.48B $8.02B $7.65B $8.18B $8.18B
Less: Treasury Stock -$1.03B -$1.08B -$1.05B -$1.01B -$1.01B
Gains/Losses Not Affecting Retained Earnings -$315.30M -$271.30M -$235.40M -$189.10M -$189.10M
-Accumulated Depreciation – – – -$1.26B -$1.26B

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Operating Cash Flow $96.40M $98.70M $108.10M $532.20M $164.90M
Net cash flow from continuing operations $96.40M $98.70M $108.10M $532.20M $164.90M
Net Income from Continuing Operations $458.60M $371.40M -$527.10M $759.90M $720.00M
Depreciation & Depletion & Amortization $41.20M $41.10M $40.90M $165.40M $42.50M
Other Non-Cash Items $6.10M -$8.70M $9.60M -$3.30M -$10.90M
Change in Working Capital $113.40M $138.40M -$168.50M $272.40M $254.10M
-Change in Receivables $18.80M -$17.60M $30.80M $19.60M $3.90M
-Change in Inventory -$200,000.00 -$7.80M -$29.90M $68.90M $51.60M
-Change in Payables and Accrued Expense -$34.70M $64.40M -$600,000.00 $1.40M $12.30M
-Change in Other Current Assets -$6.00M -$14.00M -$4.80M $12.20M -$4.20M
-Change in Other Current Liabilities $17.70M $4.60M $2.00M -$200,000.00 $300,000.00
-Change In Other Working Capital $117.80M $108.80M -$166.00M $170.50M $190.20M
Net cash flow from investing -$145.90M -$66.70M -$93.20M -$189.70M -$34.20M
Net Cash Flow from Continuing Investing Activities -$145.90M -$66.70M -$93.20M -$189.70M -$34.20M
Net PPE Purchase and Sale -$31.20M -$32.10M -$29.90M -$157.50M -$45.80M
Net Business Purchase and Sale $0.00 – – -$218.50M $0.00
Net Investment Purchase and Sale -$114.70M -$35.70M -$63.30M $186.30M $11.60M
Financing Cash Flow -$1.60M -$27.60M -$44.00M -$283.20M $3.30M
Net Cash Flow from Continuing Financing Activities -$1.60M -$27.60M -$44.00M -$283.20M $3.30M
Net Issuance Payments Of Debt -$100,000.00 -$200,000.00 -$100,000.00 -$500,000.00 -$200,000.00
Net Common Stock Issuance $0.00 -$31.50M -$47.80M -$295.50M $0.00
Proceeds from Stock Option Exercised $3.60M $4.20M $3.90M $15.80M $3.90M
Net Other Financing Charges -$5.10M – – -$3.00M -$400,000.00
Ending Cash Balance $467.10M $518.80M $509.00M $532.20M $532.20M
Net Change in Cash -$51.10M $4.40M -$29.10M $59.30M $134.00M
Beginning Cash Balance $518.80M $509.00M $532.20M $489.80M $398.20M
Effect of Exchange Rate Changes -$600,000.00 $5.40M $5.90M -$16.90M $0.00
Free Cash Flow $65.20M $66.70M $78.10M $374.60M $119.10M
Net Intangibles Purchase and Sale – – – $0.00 $0.00

Discussion

No comments yet — be the first to weigh in on BIO.

Sign in to join the discussion.

Scroll to Top